| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DBNDD1 |
| Uniprot No | Q9H9R9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-158aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMEPPEG AGTGEIVKEA EVPQAALGVP AQGTGDNGHT PVEEEVGGIP VPAPGLLQVT ERRQPLSSVS SLEVHFDLLD LTELTDMSDQ ELAEVFADSD DENLNTESPA GLHPLPRAGY LRSPSWTRTR AEQSHEKQPL GDPERQATVL DTFLTVERPQ ED |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DBNDD1重组蛋白的3篇代表性文献，信息已简化整理：
1. **文献名称**：*DBNDD1 regulates the proliferation and metastasis of colorectal cancer via the Wnt/β-catenin pathway*
**作者**：Li X, Zhang Y, et al.
**摘要**：该研究通过重组DBNDD1蛋白体外实验，发现其过表达可抑制结直肠癌细胞增殖和迁移，机制与抑制Wnt/β-catenin信号通路相关，提示DBNDD1可能作为抑癌因子发挥作用。
2. **文献名称**：*Purification and functional characterization of recombinant DBNDD1 in DNA damage response*
**作者**：Wang H, Chen J, et al.
**摘要**：作者通过大肠杆菌系统成功表达并纯化重组DBNDD1蛋白，证实其与DNA损伤修复蛋白(如ATM/ATR)存在相互作用，并参与调控细胞周期检查点激活。
3. **文献名称**：*Structural insights into DBNDD1’s role in microtubule dynamics*
**作者**：Kumar R, Lee S, et al.
**摘要**：利用重组DBNDD1蛋白的晶体结构分析，揭示了其C端结构域与微管蛋白结合的分子机制，表明DBNDD1可能通过调控微管稳定性影响细胞分裂过程。
注：以上文献为虚拟示例，实际研究中建议通过PubMed或Web of Science以“DBNDD1 recombinant protein”为关键词检索最新论文。
DBNDD1 (Dishevelled-binding antagonist of beta-catenin degradation domain-containing protein 1), also known as DACT1. is a regulatory protein involved in modulating Wnt/β-catenin signaling, a critical pathway for embryonic development, tissue homeostasis, and cancer progression. It acts as a scaffold or adaptor protein, interacting with key components of the Wnt pathway, including Dishevelled (Dvl) and β-catenin, to influence their stability, localization, or activity. DBNDD1 is characterized by its conserved degradation domain, which facilitates its role in suppressing β-catenin-mediated transcriptional activation, thereby acting as a negative regulator of Wnt signaling.
Recombinant DBNDD1 protein is engineered for in vitro studies to investigate its molecular interactions, structural features, and functional mechanisms. Produced using expression systems like *E. coli* or mammalian cells, the recombinant protein is purified to retain its biological activity, often incorporating tags (e.g., His-tag) for easier isolation. Structural studies reveal its ability to form complexes with Dvl and β-catenin, highlighting its role in sequestering these proteins or promoting their degradation via ubiquitination pathways.
Research on DBNDD1 recombinant protein has implications in understanding developmental disorders and cancers linked to dysregulated Wnt signaling. It serves as a tool for screening therapeutic agents targeting Wnt-driven pathologies. Additionally, studies suggest DBNDD1 may have context-dependent roles, as its expression is epigenetically silenced in some tumors, positioning it as a potential tumor suppressor. Its recombinant form enables detailed biochemical assays, contributing to a deeper understanding of its dual roles in development and disease.
×
